Human adenoviruses (HAdV) are widely used for in vitro and in vivo gene transfer. Viral hepatotropism, inflammatory responses and neutralization by pre-existing antibodies (NAbs) are obstacles for clinical applications of HAdV vectors. Although the multifactorial events leading to innate HAdV toxicity are far from being elucidated, there is a consensus that the majority of intravenously injected-HAdV vectors is sequestered by Kuppfer cells, probably independently of coagulation factors. In this study, we show that the adenoviral-associated humoral and innate cytokine immune responses are significantly reduced when HAdV-5 vector carrying human bovine chimeric fibers (HAdV-5-F2/BAdV-4) is intravenously injected into mice. Fiber pseudotyping modified its interaction with blood coagulation factors, as FIX and FX no longer mediate the infection of liver cells by HAdV-5-F2/BAdV-4. As a consequence, at early time points post-infection, several cytokines and chemokines (IFN-c, IL-6, IP-10, MCP-1, RANTES and MP1b) were found to be present at lower levels in the plasma of mice that had been intravenously injected with HAdV-5-F2/BAdV-4 compared with mice injected with the parental vector HAdV-5. Moreover, genetic modification of the fiber allowed HAdV-5-F2/BAdV-4 to partially escape neutralization by NAbs.
Introduction
Adenoviral vectors represent the most highly used vector in gene therapy clinical trials today despite their inherent limitations. The major hurdles for successful clinical applications appear to be the pre-existing immunity in the majority of the human population, low transduction efficiency in target cells and innate vector toxicity after systemic injection. The genetic engineering of vectors to target specific cells and to escape immune recognition has thus become a major challenge. 1 Toxicity associated with Human adenoviruses (HAdV)-5 injection is characterized by complement activation, cytokine release and subsequent vascular damage leading to a systemic inflammatory response. [2] [3] [4] [5] Induction of cytokine (interleukins IL-6, IL-10 and IL-8, tumor necrosis factor a (TNF-a) and interferon g (IFN-g)) and chemokine transcription (including macrophage inflammatory protein (MIP)-1a/b and MIP-2) is thought to be initiated by HAdVs infection. [6] [7] [8] [9] In vitro species C HAdV attach to the ubiquitous Coxsackie adenovirus receptor (CAR) using the viral fiber knob domain. 10 A second interaction with the co-receptors integrins allows for viral endocytosis into clathrin-coated pits. 11 Heparan sulfate glycosaminoglycans have also been identified as receptors for species C HAdV in vitro and in vivo.
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In vivo, the context is more complex and intravenous injection of HAdV vectors lead to transgene expression in the liver. 13 Attempts to modify in vivo HAdV liver tropism by ablating CAR and/or integrin interactions have proven to be unsuccessful. [14] [15] [16] Blood coagulation factors (FIX, FX) and the complement component C4-binding protein have major roles in the uptake of intravenously injected HAdV by hepatocytes, although scavenger receptors seem to be involved in uptake by Kupffer cells (KCs). These blood factors bridge the HAdV to the hepatocellular heparan sulfate glycosaminoglycans and to the low-density lipoprotein receptor-related protein (LPR). [17] [18] [19] KCs, liver-infiltrating monocytederived macrophages and endothelial cells seem to be the primary sources of cytokines. 20 As innate HAdV toxicity is associated with adenoviral uptake by liver cells, reduction of liver tropism would reduce the acute inflammatory response. Previous studies have shown that fiber-modified adenoviral vectors are associated with reduced liver tropism and vector toxicity. 21 The fiber protein seems to have a role in adenoviral liver tropism in vivo as shown by the use of species C HAdV pseudotyped with fiber proteins derived from human or non-human serotypes. 13 In addition, the fiber also has important roles in facilitating efficient viral attachment to cells, viral tropism and efficient intracellular trafficking of viral particles to the nucleus. 10, [22] [23] [24] A HAdV-5 vector carrying chimeric fibers composed of the N-terminal domain of human HAdV-2 and the C-terminal shaft and knob domains of the bovine Atadenovirus BAdV-4 was previously characterized to have reduced tropism for native CAR receptors and a modified cell entry pathway. 25 This chimeric vector, HAdV-5-F2/BAdV-4 also transduces cancer cells, such as MCF7 cells, SKOV3 cells and murine leukemia cells, as well as the human epidermoid carcinoma cell line A431 (unpublished data). In this study, we show the capacity of the HAdV-5-F2/BAdV-4 chimeric vector to evade neutralizing antibodies from human sera. More importantly, it was observed that intravenous injection of the vector to mice resulted in reduced liver transduction and hepatoxicity. We show evidence that the reduced liver transduction was due to minimal interaction of the vector with blood coagulation factors and the reduced hepatoxicity was associated to a reduction in the levels of several seric cytokines/chemokines (IFN-g, IL-6, IP-10, MCP-1, RANTES and MP1b)
Results

HAdV-5-F2/BAdV-4 and liver cell infection
A quality control check of each viral batch was performed before its use in any assay. Electron microscopy analysis of the HAdV-5-F2/BAdV-4 virus showed whole intact virions. No misassembly of the chimeric HAdV-5-F2/BAdV-4 penton capsomer or abnormal apical structures were observed compared with HAdV-5 ( Figure 1a ). Western blot analysis revealed that the fiber content of the chimeric vector was similar to that of the HAdV-5 virus (Figure 1a ). Reduced antiviral response against chimeric human-bovine fiber HAdV vector S Rogée et al Transduction assays showed that primary liver cells were less permissive to HAdV-5-F2/BAdV-4 than to HAdV-5 (Figure 1b, Po0.05). The viral DNA content in different organs was determined by quantitative PCR after systemic injection of 10 10 physical particles of HAdV-5-F2/BAdV-4 or HAdV-5. The viral DNA copy number levels of HAdV-5-F2/BAdV-4 was lower in the liver, but higher in the blood and spleen, in comparison to the parental HAdV-5 vector (Po0.05; Figure 1c) . In the other organs tested (lungs, heart, spleen, kidneys, intestines and ovaries), the viral copy number was inferior to 1 copy per 10 9 cells. These results suggested the attenuated ability of HAdV-5-F2/BAdV-4 to infect liver cells.
Interaction of chimeric F2/BAdV-4 fiber with blood coagulation factors
We next investigated the influence of blood coagulation factors on the interaction of the chimeric HAdV-5-F2/ BAdV-4 vector with primary liver cells. The effects of FIX, FX and FXI on physiological viral liver localization were analyzed in tissue sections after virus infusion as previously described. 19 In frozen liver sections, viruses were detected by use of an anti-hexon antibody ( Figure 2a , lower panels). IgG was used as a control (Figure 2a, upper panel) . A greater number of HAdV-5 particle aggregates were found to be associated with liver cells in the presence of FIX and FX. No difference was detected when HAdV-5-F2/BAdV-4 was injected with or without the blood factors FIX or FX. The number of aggregated viral particles was evaluated semiquantitatively by analysis of six confocal fields for each condition. The number of aggregated viral particles was found to be 25±3.7 (mean±s.e.m.) when HAdV-5 was injected alone, versus 67 ± 3.2 (2.7-fold; Po0.05) in the presence of FIX and 95±7.1 (3.8-fold; Po0.01) in the presence of FX. However, no significant change was observed with or without FXI (Figure 2b) . No variation in cell-associated virion aggregates was observed when HAdV-5-F2/BAdV-4 was perfused in the presence of FIX or FX, but interestingly, a 2.4-fold enhancement (Po0.05) was observed when it was perfused with FXI ( Figure 2b) . The reduced liver cell infection by HAdV-5-F2/BAdV-4 observed ( Figure 1 ) could therefore result from a reduced interaction of the vector with blood coagulation factors.
We then analyzed the interaction in vitro between blood coagulation factors and purified viral proteins from HAdV-5 and HAdV-5-F2/BAdV-4 using surface plasmon resonance (SPR; Figure 3 ). Individual blood factors were immobilized on sensor chips and the purified viral proteins were injected. HAdV-5 hexons were used as positive controls for interaction with FX, as previously reported. 26, 27 ( Figure 3A) . A positive interaction was detected between HAdV-5 penton protein and FIX and FX, but not with FXI ( Figure 3B , upper right panel). For the chimeric penton protein (HAdV-5 penton base carrying F2/BAdV-4 fiber), only FXI was found to interact. With chimeric fiber, the interaction was equally low with FIX, FX or FXI ( Figure 3B , lower panel), suggesting that the FXI binding site(s) would be carried by the penton base capsomer ( Figure 3B , left upper panel).
We next performed SPR analysis using viral particles and FX immoblized on chips. A very low level of interaction was observed between HAdV-5-F2/BAdV-4 and FX when compared with the strong interaction between HAdV-5 and FX ( Figure 3C, a) . Next to mimic physiological conditions in the blood circulation in which FX is not immobilized, viral particles were first preincubated with soluble FX (3-fold excess molecular ratio over viral particles) before injecting the virus-FX mix on heparin-immobilized chips. The presence of heparin on the chips mimics the expression of HSPG on the surface of hepatocytes. Under such conditions, soluble FX appeared to efficiently bridge the HAdV-5 particles to the heparin ( Figure 3C, b) . FX was also able to bridge HAdV-5-F2/BAdV-4 particles to heparin but with a much lower efficiency (compare the RU values in Figure 3C , b and c (enlargement of part of b)). A Gla domainless FX (FXGL) significantly reduced the bridging of HAdV-5-F2/BAdV-4 to heparin ( Figure 3C, c) . This strongly suggested that in our pseudo-physiological assay, soluble FX was still able to bind to HAdV-5-F2/ BAdV-4 hexons but with lower efficiency and probably not to all the hexon capsomers.
Involvement of blood coagulation factors in liver transduction by HAdV-5-F2/BAdV-4
It was previously observed that reporter gene expression mediated by HAdV-5 in primary liver cells (isolated from vector-infused livers) was enhanced in the presence of FIX or FX, whereas no change was observed with FXI. [17] [18] [19] In the case of our chimeric fiber vector HAdV-5-F2/ BAdV-4, when viruses were injected through the inferior vena cava, gene reporter b-galactosidase expression in the corresponding primary liver cells was detected at similarly low levels in the presence or absence of FIX or FX, but it was significantly enhanced in the presence of FXI (3.3-fold; Po0.01; Figure 4a ). Transduction assays of primary liver cells in vitro were performed in the presence or absence of blood coagulation factors ( Figure 4b ). FIX and FX enhanced the infection of primary hepatocytes by HAdV-5. However, only FXI, and not FIX or FX, had a significant positive effect on primary hepatocyte transduction by HAdV-5-F2/BAdV-4.
Depletion of FIX and FX using the well-described warfarin model 18 was performed in mice before virus injection ( Figure 4c ). The effect of warfarin treatment was first confirmed by a coagulation assay (Figure 4c , Table) . The prothrombin time was higher for warfarin-treated mice-plasma in comparison with the non-treated mice (Po0.001). In this assay, liver HAdV-5-mediated b-galactosidase activity was reduced after FX and FIX depletion by warfarin treatment. When a physiologically relevant amount of FX was injected after warfarin treatment, HAdV-5-mediated liver infection was restored. In contrast, there was no change observed for HAdV-5-F2/BAdV-4 in terms of vector-mediated b-galactosidase activity, with or without warfarin treatment. These data suggested that FIX and FX had minimum influence on HAdV-5-F2/BAdV-4-mediated liver infection.
Induction of inflammatory response by HAdV-5-F2/ BAdV-4
Systemic injection of HAdV-based vectors induces an acute inflammatory response. As the engineering of the fiber had an influence on the infectious process induced minimal hepatotoxicity at a dose of 10 10 PP per mouse. These data are consistent with previous studies showing that little hepatotoxicity was detectable 9 following intravenous administration with less than 10 9 PFU (E3 Â 10 10 PP) of HAdV vector. After systemic injection, the profiles of cytokine and chemokine secretion were biphasic for both vectors (Figures 5b-h ). This finding confirmed previous data showing that HAdVs induce a biphasic pattern of inflammatory cytokine gene expression in the liver. 9 An initial response was first observed at 6 h post-injection Reduced antiviral response against chimeric human-bovine fiber HAdV vector S Rogée et al (p.i.) and was likely associated with virus uptake. A second response appeared at 4-5 days p.i. and was associated with viral gene expression. During the first 6 h following injection, the secretion of all cytokines and chemokines tested in mouse plasma was lower after HAdV-5-F2/BAdV-4 injection compared with HAdV-5. After 24 h, no significant difference was observed between the two viruses, as this second phase of the immune response is mainly due to the reporter gene, b-galactosidase and basal viral gene transcription. For TNF-a, no variation in levels was noted between the two viruses regardless of the post-injection time. Taken together, these results suggested that the chimeric fiber proteins from HAdV-5-F2/BAdV-4 induced an overall weaker inflammatory response compared with HAdV-5. Reduced
Reduced neutralization of the HAdV-5-F2/BAdV-4 vector by human sera As most humans have pre-existing immunity to HAdVs, 28 we investigated whether neutralization by pre-existing antibodies (Nabs) present in human sera recognized HAdV-5-F2/BAdV-4 capsid proteins using western blot analysis of SDS-denatured virions (Figure 6a , left and right panels). Five human sera were thus tested against HAdV-5 and HAdV-5-F2/BAdV-4, and as controls the fiber proteins were detected using a monoclonal antibody directed against a conserved epitope of the N-terminal tail of the fiber (Figure 6a,  middle panel) . The F2/BAdV-4 fiber migrated with a lower apparent molecular weight than the HAdV-5 fiber (58 versus 62.5 kDa). 29 The immune reactivity of the F2/BAdV-4 fiber presented as two profiles, (i) weak recognition by human sera (Figure 6a, right panel) , and (ii) absence of detectable signal (Figure 6a, left panel) .
Ten different human sera were also tested for their neutralizing activity against HAdV-5-F2/BAdV-4 in an inhibitory infection assay using CHO-CAR cells, and compared with HAdV-5 ( Figure 6b ). The effects of NAbs could be compared using CHO-CAR cells because this cell line has been shown to be permissive to both HAdV-5 and HAdV-5-F2/BAdV-4. 29 HAdV-5-F2/BAdV-4 showed a higher infectivity than HAdV-5, in the presence of human sera at all dilutions used (Figure 6b) . The data 21d  10d  7d  5d  24h  6h  1h  21d  15d  7d  48h  24h  6h  3h  1h   30d  21d  15d  7d  48h  24h  6h  3h  1h   30d  21d  7d  48h  24h  6h  3h  1h   21d  15d  7d  48h  24h  6h  3h  1h   21d  15d  7d  48h  24h  6h  3h  1h   21d  15d  7d  48h  24h  6h  3h  1h 21d 15d 7d 48h 24h 3h 
Discussion
Adenoviral vectors have been extensively used in clinical studies, but their use is limited due to their wide and non-specific biodistribution in tissues and the innate vector toxicity. Intravenous administration of HAdV-5 vectors in mammals leads to rapid transduction of the liver. 30, 31 The uptake of HAdV vector into KCs and hepatocytes leads to HAdV-mediated inflammation and liver toxicity. 30 The vitamin K-dependent blood coagulation factors FIX and FX have a major role in the adenoviral infection of hepatocytes, 18, 19 which occurs by direct interaction of FIX and FX with the adenovirus capsid proteins and seems to be mediated by HSPG.
FX has been shown to bind to the HVRs (Hyper-VariableRegions) of HAdV-5 hexons. 26, 27 In this report, the biological impact of a fiber-modified vector on liver cell infection and the vector-associated inflammatory response was investigated. The HAdV-5-F2/BAdV-4 was found to have an attenuated capacity to infect primary liver cells (Figure 1b) . This finding could be explained by a distinct infection mechanism in liver cells, such as endocytosis by caveolae, as was previously shown in in vitro infection 25 assay. Both HAdV-5 and HAdV-5-F2/BAdV-4 virions are formed from the same hexon/penton base capsomers and only differed by their fiber proteins. In this study, we showed that the in vitro interactions between blood coagulation factors (FIX, FX, FXI) and HAdV-5-F2/BAdV-4 penton proteins were different ( Figures 3A and B) . The SPR data using viral particles suggested that in a pseudo-physiological assay (complexes FX/viral particles injected through immobilized heparin), FX was still able to bind to HAdV-5-F2/ BAdV-4 hexons but with a lower affinity and probably not with all the hexons ( Figure 3C ). Several hypotheses could be proposed to explain this change in protein interaction. (i) First, the physicochemical properties of HAdV-5-F2/BAdV-4 fiber could modulate protein interactions, as previously suggested. 32 The chimeric HAdV-5-F2/BAdV-4 fiber has a predicted pI value of 5.35 and FX a pI value of 5.68, whereas HAdV-5 fiber has a higher pI value of 6.06. This change in the chimeric fiber pI corresponded to an increase in acidic, repulsive charges, which could alter the interaction of HAdV-5-F2/BAdV-4 with FX ( Figure 3C ). On the contrary, the more basic FXI-predicted pI value of 8.47 could lead to a higher affinity for the chimeric particles ( Figure 3B ).
(ii) Another explanation could be related to the length and the flexibility of the fibers that could influence the protein interaction.
33 F2/BAdV-4 fiber is shorter than HAdV-5 fiber and does not contain the conserved KLGXGLXFD/N motif proximal to the knob domain, as described for subgroup D HAdV-37, 33 suggesting that the chimeric fiber has increased rigidity. (iii) These two hypotheses were not mutually exclusive.
Our results suggested that (i) the serotype 5 penton base could carry FXI-binding site(s), as the chimeric HAdV-5-F2/BAdV-4 penton protein bound to FXI, whereas HAdV-5 penton protein did not, perhaps because they are less exposed, and (ii) that the hexon capsomers of HAdV-5-F2/BAdV-4 had lower binding activity to FX than those on HAdV-5. These findings are reminiscent of previous studies showing that pseudotyping of the HAdV-5 vector with a serotype 3 fiber resulted in strong attenuation of liver uptake. 34 More recently, the observed difference in the affinity of FX for free HAdV-5 hexons and whole virions suggests that the interaction between FX and the HAdV-5 virion might involve several capsomers. 34 Our own data support the latter hypothesis and furthermore, they suggest that the interaction between HAdV-5-based vectors and blood coagulation factors and its positive effect on the liver uptake of the vectors depend on two viral parameters: (i) the existence of major sites (for example, in hexon HVRs) and minor sites (for example, in the penton base or fiber shaft domain), and (ii) their accessibility and reactivity, which could be highly sensitive to the structure of the apical capsomers, penton base and/or fiber. Extrinsic sequences inserted into the fiber, as in the 62.5 kDa Reduced antiviral response against chimeric human-bovine fiber HAdV vector S Rogée et al chimeric HAdV-5-F2/BAdV-4 penton may modulate auxiliary binding sites in the fiber, cause steric interference, or trigger conformational changes that hide the major binding sites on the hexon HVRs or reduce the bridging of coagulation factors with hepatocellular receptors.
Systemic injection of HAdV-based vectors induces an acute inflammatory response, and cellular defensive responses are responsible for HAdV-associated toxicity. 9 Both HAdV-5 and HAdV-5-F2/BAdV-4 induced minimal hepatotoxicity at 10 10 PP/mouse (Figure 5a ) but the HAdV-5-F2/BAdV-4 vector induced a weaker inflammatory response (Figures 5b-h) . Interaction of adenoviral vectors with the liver is a complex process and viral uptake by liver cells is causatively associated with innate HAdV toxicity. The innate and adaptive immune systems in the liver are triggered by a variety of intrahepatic cells (parenchymal liver cells, hepatocytes), endothelial cells, liver-resident macrophages (Kupffer cells) and lymphocytes (NK and NKT cells). The uptake of HAdV-5-F2/BAdV-4 requires interaction with a co-receptor, putatively the chondroitin sulfate receptor. 35 This protein is mainly detected in the vessel walls of veins and in the adventitial layer of arteries 36 and its infective capacity is independent of hCAR and HSPG, 29, 35 which are found on hepatocytes. Such differences in the expression of receptors or co-receptors could explain why HAdV-5-F2/BAdV-4 is able to infect different types of liver cells compared with HAdV-5. A difference in cellular entry pathway could also result in modification of intracellular-signaling pathways and subsequent cytokine and chemokine secretion (Figures  5b-h) . In dendritic cells, induction of TNF-a is mediated by the PI3K signaling pathway. 37 The caveolae pathway activates the PI3K pathway and, subsequently, the TNF-a pathway. 38 This observation may explain why any reduction in the TNF-a levels was observed after HAdV-5-F2/BAdV-4 injection (Figure 5d ).
As described above for the HAdV-35 vector 39,40 and the chimeric vector (HAdV-5-F7, -F41), 21 we assume that the fiber contributes to the potent immunogenicity of HAdV-5-F2/BAdV-4 by determining viral tropism and the cell entry mechanism (Figures 1-3 ) and consequently the activation of cell signaling pathways leading to the induction of cytokines ( Figure 5 ). Neutralization assays with human sera were performed to analyze the potential of HAdV-5-F2/BAdV-4 in clinical trials. The presence of the chimeric F2/BAdV-4 fiber resulted in a net decrease in neutralization activity (Figure 6b ). This finding indicated that the chimeric F2/BAdV-4 fiber allowed the HAdV-5-F2/BAdV-4 vector to escape neutralization by NAbs in human sera. Anti-fiber antibodies preferentially recognize the native trimeric form of the fiber protein, suggesting that they recognize conformational epitopes. This finding may explain why we obtained reduced evasion from NAbs with HAdV-5-F2/BAdV-4. Indeed, HAdV-5-F2/BAdV-4 is a HAdV-5 vector carrying chimeric fibers composed of the N-terminal domain of human HAdV-2 and the C-terminal shaft and knob domains of the bovine Atadenovirus BAdV-4. The genetic engineering of the fiber probably induced conformational changes, which destroyed or masked the fiber epitopes. Similar seroprevalence (a reduction of 50%) was observed with HAdV-35 and a pseudotyped vector with a chimeric fiber (HAdV-5-F45). 39, 41 Human sera mainly carry anti-knob and anti-hexon NAbs but in certain sera, anti-hexon antibodies represent the major population of NAbs. 42 A combination of knob deletion and hexon switching could therefore be an effective strategy employed for HAdV vectors to evade anti-HAdV NAbs. Our fiber engineering approach using a non-human fiber protein ablated most fiber epitopes recognized by NAbs in human sera. Nevertheless, it does not prevent the recognition of epitopes localized on other non-modified capsid proteins, as was also observed for HAdV-5-F45. 41 In conclusion, this study showed that pseudotyping of HAdV-5 with a non human-bovine chimeric fiber F2/ BAdV-4 could modulate the influence of blood factors in hepatocyte infection, likely by altering the interaction between FX and hepatocellular receptors. In addition, engineering of the fiber also resulted in (i) reduced expression of a reporter gene in liver cells in vivo, (ii) decreased neutralization by pre-existing NAbs in human sera, and (iii) reduced capsid-mediated inflammatory response.
Materials and methods
Cell culture
CHO-CAR cell lines (provided by Jeff Bergelson
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) were cultured in Dulbecco Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% non-essential amino acids. The cells were maintained in a humidified incubator with 5% CO 2 and were passaged twice per week. Primary liver cells were obtained from mice after liver isolation and blood depletion. Livers were then flushed by collagenase perfusion (PBS supplemented with 50 mM HEPES; 5 mM CaCl 2 , 2H 2 O; 0.025% type IV collagenase; pH 7.4) crushed and filtrated through a 70 mm cell strainer to isolate the liver cells. The cells were then plated and cultured in DMEM supplemented with 10% FBS, non-essential amino acids (1%) and antibiotics (1%). The viability of the primary liver cells was assessed by propidium iodide labeling.
Adenovirus growth
The HAdV-5-F2/BAdV-4 and HAdV-5 vectors were amplified and purified following conventional protocols. The purified viral particles were quantified by measuring the viral DNA at 260 nm and the virus titer expressed as viral physical particles (PP) per ml. The genetic constructions of the chimeric virus have been described previously. 43, 29 For the chimeric virus, the junction between HAdV-2 fiber and BAdV-4 fiber occured in the shaft repeat 7 at the GKL (glycine-lysine-leucine) motif sequence to generate the chimeric fiber F2/BAdV-4. The fiber swap changed its isoelectric point (pI) from 6.03 (HAdV-2 and -5 fibers) to 5.35 (BAdV-4 fiber).
Purification of adenoviral capsid proteins
Adenovirus complete penton (penton base + fiber) and free unbound fiber were isolated from lysates of HAdV-5-infected 293 cells. Adenoviral proteins were purified according to a conventional protocol adapted to fast protein liquid chromatography. Protein samples were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting as previously described.
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b-Galactosidase activity
The b-galactosidase activity was determined by cytometric analyses as previously described. 35 . For this purpose, cells were infected with viruses in serum-free medium. At 24 h post-infection, cells were washed and cytometric analyses were performed after reaction with fluorescein DI-(b-D-galacto-pyranoside) (Sigma-Aldrich, Lyon, France) at a final concentration of 0.1 mg ml -1 for 10 min at 37 1C.
Impact of coagulation factors on liver cell infection by HAdV in vivo and ex vivo
Eight-week-old female Balb/C mice were purchased from Janvier Laboratories and maintained in compliance with institutional protocols. The vena porta and inferior vena cava of mice were cannulated, and the liver was flushed with PBS through the vena porta. When the liver color changed from dark brown to light yellow-brown, the inferior vena cava and the vena porta were ligated to allow asanguinous and isolated liver perfusion. HAdVs (2.5 Â 10 10 PP/ml) and 8 mg ml -1 of FIX, FX or FXI (Biopep) prepared in 8 ml DMEM were then infused through the inferior vena cava. The liver was further incubated at 37 1C for 45 min.
Primary liver cells were infected with 1000 physical particles (PP)/cell of virus incubated with or without human coagulation factors in 750 ml serumfree medium. Human coagulation factors were used at 1UI (FIX at 6 mg ml -1 , FX at 10 mg ml -1 and FXI at 4 mg ml -1 ). A total of 750 ml of medium supplemented with 4% FBS was added 2 h later. At 24 h post-infection, the b-galactosidase activity was analyzed by flow cytometry.
Warfarin treatment of mice, which results in depletion of FIX and FX, was analyzed as described by Parker and collaborators. 18 Rescue by treatment with 33 mg of FX was performed before injection of HAdV-5. b-galactosidase expression in liver cells was quantified by use of the Beta-Glo Assay System (Promega, Charbonnières, France). To assess the effect of warfarin on clotting times (CTs), 50 ml samples of citrated plasma, taken immediately after warfarin treatment, and human placental thromboplastin/calcium chloride reagent (Innovin, Dade Behring, Milton Keynes, UK) were mixed in a glass clotting tube at 37 1C and CT was determined visually (Hematology and Transfusion Unit, Biology and Pathology Center of Lille). Plasma samples with a CT above 60 s were considered incoagulable. PP of viruses were suspended in 100 ml of phosphate-buffered saline (PBS) and injected into the tail vein of the mice. Control mice received 100 ml of PBS. Animals were killed 24 h after viral infusion. Blood samples were collected by intracardiac puncture. A cardiac saline perfusion was then performed to flush blood from the organs. Blood, liver, lungs, heart, spleen, kidneys, intestines and ovaries were removed and individually incubated in 2 ml of lysis buffer (100 mM NaCl, 25 mM EDTA, 10 mM Tris-HCl pH 8, 0.5% SDS, 0.5 mg ml -1 proteinase K) at 56 1C overnight. DNA was extracted using a phenol/chloroform/isoamyl alcohol (25:24:1) solution and quantified by measurement of absorbance at 260 and 280 nm. Aliquots (250 ng) of total DNA were subjected to quantitative real-time PCR using duplicate samples. The mouse albumin gene was used as a control. For adenovirus gene detection, the following oligonucleotides were used: sense primer: 
Cytokines and ALT quantification in mouse plasma
The levels of plasma cytokines were determined at different times after intravenous administration of 10 10 PP of HAdV. Blood samples were collected in heparintreated Eppendorf tubes. Following centrifugation for 5 min at 1000 g, the cells were pelleted and plasma samples were collected. The levels of IL-6, TNF-a and IFN-g were evaluated using the corresponding ELISA kits (PERBIO). IP-10, MCP-1, MIP1b and RANTES plasma levels were determined by flow cytometry using a multiplex kit (TEBU Biosciences, Tebu-bio, Le Perray en Yvelines, France). The plasma levels of alanine transaminase (ALT), a marker of hepatocellular damage, were analyzed by conventional assays at the Biochemistry Unit of the University Hospital (CHR), Lille, France. Plasma samples obtained from at least 10 mice per vector were analyzed in duplicate.
HAdV neutralization assays
After patient consent, the Hematology Unit of the CHR, Lille, France collected 10 human serum samples. A total of 6 Â 10 8 PP of HAdV were incubated with undiluted (0) or diluted serum (1/5-1/200) for 2 h at 37 1C in PBS in a final volume of 300 ml. The vector-serum mixture was added to 750 ml of DMEM medium containing 4% FCS and incubated with 6 Â 10 5 CHO-CAR cells. Twenty-four hours post-infection, the b-galactosidase activity was measured as previously described.
Gel electrophoresis and western blot analysis
Viral protein samples were separated on 4-8% gradient gel by SDS-PAGE and the proteins transferred onto a Reduced antiviral response against chimeric human-bovine fiber HAdV vector S Rogée et al nitrocellulose membrane as previously described. 49 After saturation in fat-free milk, the blots were incubated in 10 ml either with a solution of primary monoclonal antibody against adenovirus fiber (1/1200 dilution, clone 4D2, recognizing the first 17 amino acids of the N terminus; Interchim) or with human serum (1/100). Blots were then incubated in 40 ml of the appropriate HRP-conjugated secondary antibody (1/10 000), rinsed and developed by chemiluminescence (ECL, Amersham, Amersham-GE Healthcare Europe GmbH, Saclay, France).
Electron microscopy
For negative staining of virus, carbon-coated grids were floated on drops of virus suspension for 10 min. Excess fluid was removed by use of filter paper. The grids were then successfully floated on drops of staining solution (2% uranyl acetate) for 1 min followed by PBS for 1 min. After being air-dried, the grids were observed under a transmission electron microscope (Zeiss EM902).
Surface plasmon resonance assays
HBS (GE-Healthcare, Saclay, France) supplemented with 2 mM CaCl 2 was used as running buffer in experiments at a flow-rate of 5 ml min -1 for complet viral particle or 20 ml min -1 for viral-purified proteins. Immobilization on CM4 sensorship were performed using FIX, X and XI at 0.1 mg ml -1 (Cryopep) diluted in 10 mM sodium acetate buffer pH 4.0; 4.5 and 5.0, respectively. They were injected for 10 min on EDC-NHS activated flow-cell. Viruses (2.10 9 PP in 25 ml of running buffer) and purified viral protein samples (4 ng in 100 ml) were injected and signals were automatically subtracted from the background of an ethanolamine deactivated EDC-NHS flow-cell. For heparin immobilization, two EDC-NHSactivated flow-cells were injected for 10 min with 0.1 mg ml -1 streptavidin in 10 mM sodium acetate pH 4.2, then inactivated by 10 min injection of ethanolamine. Heparin immobilization was done by injection (15 ml) of 9 kDa biotinylated heparin at 0.1 mg ml -1 , on one flow cell whereas the other flow cell was used as control. Runs were done in triplicate.
Statistical analyses
For all experiments, the data are presented as the mean+/-s.e.m. of three independent experiments performed in duplicate. Statistical analysis was performed using the Mann-Whitney test.
